Stock Market News1 week Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs The Wall Street Journal
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
XEli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
X